Totalis Behavioral Health is the first in Southern NJ to offer EarliPoint® Health — the first FDA-cleared eye-tracking technology to help clinicians diagnose autism in children as young as 16 months, cutting wait times from months to weeks.
children in the U.S. are diagnosed with autism
median age of earliest documented autism diagnosis – but answers may be possible much sooner.
Earlipoint is FDA-cleared for children ages 16 months to approximately 7.9 years (95 months).
EarliPoint is not a screening questionnaire. It is a clinically validated, FDA-cleared device that measures how your child’s eyes move as they watch a short video — capturing data that reveals patterns in social attention and cognitive engagement linked to autism.
Traditional autism evaluations rely heavily on observation and parent-reported behavior, which — while valuable — can be subjective and time-consuming. Waitlists for specialist evaluations often stretch six months to over a year.
EarliPoint changes that. Using advanced eye-tracking sensors and algorithms developed over decades of research at Yale University and Emory University, the system generates objective, quantifiable data that supports a clinician’s diagnostic decision when presented to them
The technology does not replace your clinician. It gives them powerful, precise data so they can move forward with confidence.
We’ve designed the intake process to be as simple as possible for families who are already carrying a lot. Here’s what to expect.